MATEON LAUNCHES ITS AI TELEMEDICINE PLATFORM FOR POST MARKETING SURVEY TO SUPPORT ITS DRUG PRODUCT FOR INDIA, PULMOHEAL™
01 févr. 2021 07h00 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases,...
MATEON LAUNCHING MOBILE APP, ARTIHEALTH™, FOR REMOTE RESPIRATORY HEALTH ASSESSMENT
25 janv. 2021 07h00 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases,...
MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 THERAPEUTIC
13 janv. 2021 07h00 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported positive...
MATEON’S GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST COVID-19 ENROLLS AND TREATS ITS FIRST PATIENT
30 déc. 2020 10h46 HE
|
Mateon Therapeutics, Inc.
-FPI FOR C001 PHASE 2 TRIAL AGAINST COVID-19 AGOURA HILLS, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today that it has...
MATEON TO HOST VIRTUAL WEBINAR ADDRESSING COVID-19 AND THERAPIES AYURVEDA AND ARTEMISIA ON DECEMBER 16, 2020
09 déc. 2020 07h00 HE
|
Mateon Therapeutics, Inc.
Featuring Global Experts in Ayurveda and PharmacologyDecember 16, 2020 7 AM PST- 10 AM EST- 8:30 PM ISTPanel Discussion and Q & A to follow Agoura Hills, California, Dec. 09, 2020 (GLOBE...
DEVELOPMENT UPDATE FOR ARTIVEDA™/ARTISHIELD™ AGAINST COVID-19
30 nov. 2020 07h00 HE
|
Mateon Therapeutics, Inc.
--75% IMPROVEMENT BY DAY 2 ON ARTIVEDA™ AGOURA HILLS, California, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics...
MATEON PROVIDES CORPORATE UPDATE AND ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS
16 nov. 2020 06h55 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB: MATN) today announced financial results for the third quarter ended September...
MATEON THERAPEUTICS AND WINDLAS BIOTECH ENTER INTO DEFINITIVE AGREEMENT TO COMMERCIALZE ARTIVEDA™ AGAINST COVID-19
11 nov. 2020 07h00 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today an agreement with Windlas Biotech Pvt. Ltd. of...
MATEON’S C001- A GLOBAL PHASE 2 STUDY FOR OT-101 AGAINST COVID-19- RECEIVED CLEARANCE FOR PATIENT ENROLLMENT
04 nov. 2020 07h00 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today the receipt of approval from Instituto Nacional de Salud...
MATEON TO HOST VIRTUAL SYMPOSIUM ADDRESSING COVID-19 ON NOVEMBER 11, 2020
02 nov. 2020 07h00 HE
|
Mateon Therapeutics, Inc.
“Advancing Ayurveda Through Ethnobiology Drug Development”Topics Include Mateon’s ARTIShield™ for the Treatment of COVID-19 and COVID-19/Influenza Coinfection AGOURA HILLS, Calif., Nov. 02, 2020 ...